Role of 5α-reductase inhibitors in prostate cancer prevention and treatment (Q34263508)

1 August 2017

Role of 5α-reductase inhibitors in prostate cancer prevention and treatment (English)

1 reference

1 August 2017

1 reference

Faris Azzouni

1

1 reference

PubMed ID

22446342

1 August 2017

James Mohler

series ordinal

2

1 reference

PubMed ID

22446342

1 August 2017

language of work or name

English

0 references

publication date

23 March 2012

1 reference

1 August 2017

1 reference

1 August 2017

79

1 reference

1 August 2017

1197-1205

1 reference

1 August 2017

6

1 reference

Immunocytochemical evidence for differential subcellular localization of 5 alpha-reductase isoenzymes in human tissues

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

5α-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Markers and meaning of primary treatment failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

The influence of finasteride on the development of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Effect of dutasteride on the risk of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Stud

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Time trends and local variation in primary treatment of localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Influence of prostate volume in the detection of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4-7, clinically localized prostate cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Re: The Prostate Cancer Prevention Trial: design, biases and interpretation of study results. P. J. Goodman, I. M. Thompson, Jr., C. M. Tangen, J. J. Crowley, L. G. Ford and C. A. Coltman, Jr., J Urol, 175: 2234-2242, 2006.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Low-Activity V89L Variant in SRD5A2 Is Associated with Aggressive Prostate Cancer Risk: An Explanation for the Adverse Effects Observed in Chemoprevention Trials Using 5-Alpha-Reductase Inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Quantitation of apoptotic activity following castration in human prostatic tissue in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Treatment with finasteride following radical prostatectomy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Intermittent use of testosterone inactivating pharmaceuticals using finasteride prolongs the time off period

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

The androgen axis in recurrent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.01.024

10.1016/J.UROLOGY.2012.01.024

7 January 2021

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

22446342